Anti-CD137 Cancer Immunotherapy Suppresses Tumor Growth-Letter

Anti-CD137 Cancer Immunotherapy Suppresses Tumor Growth-Letter

10.1158/0008-5472.CAN-17-2997

Saved in:

書目詳細資料
Main Authors:	Dharmadhikari, Bhushan, Zeng, Qun, Wu, Meihui, Schwarz, Herbert
其他作者:	PHYSIOLOGY
格式:	Letter
語言:	English
出版:	AMER ASSOC CANCER RESEARCH 2023
主題:	Science & Technology Life Sciences & Biomedicine Oncology LIGAND 4-1BB
在線閱讀:	https://scholarbank.nus.edu.sg/handle/10635/239111
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

CD137 ligand interacts with CD32a to trigger reverse CD137 ligand signaling
由: Zeng, Qun, et al.
出版: (2023)

CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8(+) T cells to Tc1 phenotype
由: Dharmadhikari, Bhushan, et al.
出版: (2023)

Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
由: Luu, Khang, et al.
出版: (2023)

Induction of CD137 expression by viral genes reduces T cell costimulation
由: Wu, Meihui, et al.
出版: (2023)

ROLE OF CD137-CD137L INTERACTION IN MICROGLIA-MEDIATED IMMUNE RESPONSE
由: NUR SHARALYN BINTE ABDULLAH
出版: (2016)

CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases
由: Wong, HY, et al.
出版: (2023)

The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention
由: Luu, Khang, et al.
出版: (2023)

EPSTEIN-BARR VIRUS-INDUCED CD137 IN NASOPHARYNGEAL CARCINOMA
由: SASHIGALA D/O PONNALAGU
出版: (2021)

CD137L- DENDRITIC CELLS HAVE A NOVEL INFLAMMATORY PHENOTYPE AND INDUCE A POTENT TC1 RESPONSE AGAINST EPSTEIN-BARR VIRUS
由: BHUSHAN DHARMADHIKARI
出版: (2017)

CD137L, a driver of harmful inflammation in the nervous system
由: Wong, Hiu Yi, et al.
出版: (2024)

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma (NPC).
由: Walsh, Robert John, et al.
出版: (2023)

Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype
由: Harfuddin, Z, et al.
出版: (2020)

Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors
由: Prasad, Mukul, et al.
出版: (2023)

The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus
由: Mak, A., et al.
出版: (2021)

CD137 Ligand-CD137 Interaction is Required For Inflammasome-Associated Brain Injury Following Ischemic Stroke
由: Fann, DY, et al.
出版: (2023)

Signal transduction mechanisms of CD137 ligand in human monocytes
由: Sollner, L., et al.
出版: (2011)

Deletion of CD137 ligand exacerbates renal and cutaneous but alleviates cerebral manifestations in Lupus
由: Mak, A., et al.
出版: (2021)

Regulatory t cells inhibit t cell activity by downregulating cd137 ligand via cd137 trogocytosis
由: Luu, Khang, et al.
出版: (2022)

Resisting resistance to cancer immunotherapy
由: RAGHAV SUNDAR, et al.
出版: (2021)

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit
由: Nickles, Emily, et al.
出版: (2023)

CHARACTERISATION OF THE ANTI-VIRAL T-CELL RESPONSE INDUCED BY HUMAN CD137 LIGAND DENDRITIC CELLS
由: ZULKARNAIN HARFUDDIN
出版: (2014)

ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer (vol 11, 184, 2019)
由: Wang, Yan, et al.
出版: (2023)

AKT-DRIVEN GLYCOLYSIS CONTRIBUTES TO THE SUPERIOR FUNCTION OF CD137L-DCS, WHOSE DIFFERENTIATION IS MEDIATED BY CD137L AND CD32A
由: ZENG QUN
出版: (2020)

Induction of CD137 expression by Epstein-Barr Virus facilitates immune escape of infected cells
由: Wu, M, et al.
出版: (2023)

Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype
由: SCHWARZ HERBERT
出版: (2023)

The tumor suppressor Zinc finger protein 471 suppresses breast cancer growth and metastasis through inhibiting AKT and Wnt/beta-catenin signaling (vol 12, 173, 2020)
由: Tao, Chunfang, et al.
出版: (2023)

ELUCIDATION OF THE PATHOGENIC ROLE OF CD137 LIGAND IN A MURINE MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS
由: ANSELM MAK
出版: (2018)

Tumoral STING is required for effective anticancer immunity
由: Suter, Manuel Adrian, et al.
出版: (2023)

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
由: Berry, Sneha, et al.
出版: (2021)

Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment
由: Goh, Kah Yee, et al.
出版: (2024)

ROLE OF CD137 SIGNALING IN IMMUNE DEVIATION OF HODGKIN LYMPHOMA AND ITS UTILISATION IN DEVELOPMENT OF IMMUNOTHERAPY
由: SAKTHI RAJENDRAN
出版: (2017)

CD137 negatively affects "browning" of white adipose tissue during cold exposure
由: RAJ KAMAL SRIVASTAVA, et al.
出版: (2021)

CD137, implications in immunity and potential for therapy.
由: Thum, E., et al.
出版: (2011)

Tumor necrosis factor receptor 1 associates with CD137 ligand and mediates its reverse signaling
由: Moh, M.C., et al.
出版: (2014)

CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives
由: Zeng, Q., et al.
出版: (2021)

Mammography screening is associated with more favorable breast cancer tumor characteristics and better overall survival: Case-only analysis of 3,739 Asian breast cancer patients.
由: Hartman, Mikael, et al.
出版: (2023)

Biological activities of reverse signal transduction through CD137 ligand
由: Schwarz, H.
出版: (2011)

Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs
由: Zeng, Q, et al.
出版: (2019)

Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting
由: Kang Yi Lee, et al.
出版: (2022)

The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy
由: Wo, Yu Jun, et al.
出版: (2020)